Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A. Cork MJ, et al. Among authors: arkwright pd. Br J Dermatol. 2021 May;184(5):857-870. doi: 10.1111/bjd.19460. Epub 2020 Oct 9. Br J Dermatol. 2021. PMID: 32969489 Free PMC article. Clinical Trial.
Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial.
Berth-Jones J, Arkwright PD, Marasovic D, Savani N, Aldridge CR, Leech SN, Morgan C, Clark SM, Ogilvie S, Chopra S, Harper JI, Smith CH, Rook GA, Friedmann PS. Berth-Jones J, et al. Among authors: arkwright pd. Clin Exp Allergy. 2006 Sep;36(9):1115-21. doi: 10.1111/j.1365-2222.2006.02558.x. Clin Exp Allergy. 2006. PMID: 16961710 Clinical Trial.
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M, Ardeleanu M, Teper A, Akinlade B, Gadkari A, Eckert L, Kamal MA, Ruddy M, Graham NMH, Pirozzi G, Stahl N, DiCioccio AT, Bansal A. Cork MJ, et al. Among authors: arkwright pd. Br J Dermatol. 2020 Jan;182(1):85-96. doi: 10.1111/bjd.18476. Epub 2019 Oct 8. Br J Dermatol. 2020. PMID: 31595499 Free PMC article. Clinical Trial.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L, Weisman J, O'Malley JT, Patel N, Hardin M, Graham NMH, Ruddy M, Sun X, Davis JD, Kamal MA, Khokhar FA, Weinreich DM, Yancopoulos GD, Beazley B, Bansal A, Shumel B. Paller AS, et al. Among authors: arkwright pd. J Am Acad Dermatol. 2020 Nov;83(5):1282-1293. doi: 10.1016/j.jaad.2020.06.054. Epub 2020 Jun 20. J Am Acad Dermatol. 2020. PMID: 32574587 Free article. Clinical Trial.
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.
Paller AS, Wollenberg A, Siegfried E, Thaçi D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O'Malley JT, Khokhar FA, Vakil J, Bansal A, Rosner K, Shumel B, Levit NA. Paller AS, et al. Among authors: arkwright pd. Paediatr Drugs. 2021 Sep;23(5):515-527. doi: 10.1007/s40272-021-00459-x. Epub 2021 Aug 31. Paediatr Drugs. 2021. PMID: 34462864 Free PMC article. Clinical Trial.
212 results